Among the inhibitory checkpoints, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) expressed by T cells are the most studied and are promising targets for cancer immunotherapy. Here, CTLA4 is linked to cancer.